CY1122945T1 - Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου - Google Patents

Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου

Info

Publication number
CY1122945T1
CY1122945T1 CY20201100469T CY201100469T CY1122945T1 CY 1122945 T1 CY1122945 T1 CY 1122945T1 CY 20201100469 T CY20201100469 T CY 20201100469T CY 201100469 T CY201100469 T CY 201100469T CY 1122945 T1 CY1122945 T1 CY 1122945T1
Authority
CY
Cyprus
Prior art keywords
cancer
treatment
uridine
c6alkyl
dioxolane
Prior art date
Application number
CY20201100469T
Other languages
Greek (el)
English (en)
Inventor
Richard Bethell
Björn KLASSON
Fredrik ÖBERG
Anders Eneroth
Original Assignee
Medivir Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Aktiebolag filed Critical Medivir Aktiebolag
Publication of CY1122945T1 publication Critical patent/CY1122945T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20201100469T 2014-08-25 2020-05-22 Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου CY1122945T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22
PCT/EP2015/069370 WO2016030335A1 (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1122945T1 true CY1122945T1 (el) 2021-10-29

Family

ID=54014804

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100469T CY1122945T1 (el) 2014-08-25 2020-05-22 Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου

Country Status (24)

Country Link
US (7) US10144750B2 (enExample)
EP (2) EP3186244B1 (enExample)
JP (2) JP6663424B2 (enExample)
KR (2) KR102398714B1 (enExample)
CN (4) CN111269264A (enExample)
AU (2) AU2015308988C1 (enExample)
BR (1) BR112017003898B1 (enExample)
CA (2) CA2956251C (enExample)
CY (1) CY1122945T1 (enExample)
DK (2) DK3572410T3 (enExample)
EA (2) EA033300B1 (enExample)
ES (2) ES2796089T3 (enExample)
HR (1) HRP20201023T1 (enExample)
HU (2) HUE050705T2 (enExample)
IL (2) IL250344B (enExample)
MX (1) MX369649B (enExample)
MY (2) MY188089A (enExample)
NZ (2) NZ729118A (enExample)
PH (2) PH12017500184A1 (enExample)
PL (2) PL3572410T3 (enExample)
PT (2) PT3186244T (enExample)
SG (3) SG10202001117YA (enExample)
WO (1) WO2016030335A1 (enExample)
ZA (1) ZA201802864B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102398714B1 (ko) * 2014-08-25 2022-05-17 메디비르 아베 암 치료를 위한 우리딘의 디옥솔란 유사체
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
RS62593B1 (sr) 2015-12-11 2021-12-31 NuCana plc Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
CA3014769C (en) * 2016-03-02 2024-01-09 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
MA46839A (fr) * 2016-11-18 2021-03-24 Neurovive Pharmaceutical Ab Promédicaments hépatiques d'ionophores de protons mitochondriaux
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2020171757A1 (en) * 2019-02-18 2020-08-27 Medivir Aktiebolag Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
JP7709456B2 (ja) * 2020-04-15 2025-07-16 メディヴィル・アクチエボラーグ 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
KR20030096226A (ko) * 2000-10-13 2003-12-24 샤이어 바이오켐 인코포레이티드 개선된 세포간 전달을 보이는 디옥소란 동족체
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
CN105934438A (zh) * 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
KR102398714B1 (ko) * 2014-08-25 2022-05-17 메디비르 아베 암 치료를 위한 우리딘의 디옥솔란 유사체

Also Published As

Publication number Publication date
NZ762628A (en) 2023-04-28
IL250344B (en) 2020-01-30
AU2018201980A1 (en) 2018-04-12
AU2018201980B2 (en) 2019-05-16
KR20170046736A (ko) 2017-05-02
CA2956251C (en) 2022-10-25
IL266766B (en) 2020-05-31
EA201790328A1 (ru) 2017-08-31
HUE059640T2 (hu) 2022-12-28
US20230382931A1 (en) 2023-11-30
US10822360B2 (en) 2020-11-03
MX369649B (es) 2019-11-15
KR102396905B1 (ko) 2022-05-13
EA201890648A2 (ru) 2018-08-31
PT3572410T (pt) 2022-09-15
US20190389890A1 (en) 2019-12-26
US20200239502A1 (en) 2020-07-30
CN110804072A (zh) 2020-02-18
EP3186244B1 (en) 2020-04-22
IL250344A0 (en) 2017-03-30
ES2927212T3 (es) 2022-11-03
US11447511B2 (en) 2022-09-20
IL266766A (en) 2019-07-31
JP2020090535A (ja) 2020-06-11
US10336780B2 (en) 2019-07-02
JP6905609B2 (ja) 2021-07-21
SG10201911558UA (en) 2020-01-30
DK3572410T3 (da) 2022-08-29
CN111269264A (zh) 2020-06-12
ZA201802864B (en) 2019-07-31
US20230117570A1 (en) 2023-04-20
HRP20201023T1 (hr) 2020-10-16
US10144750B2 (en) 2018-12-04
WO2016030335A1 (en) 2016-03-03
PT3186244T (pt) 2020-05-29
EP3186244A1 (en) 2017-07-05
SG10202001117YA (en) 2020-04-29
MY198325A (en) 2023-08-24
EA033300B1 (ru) 2019-09-30
ES2796089T3 (es) 2020-11-25
US20210054008A1 (en) 2021-02-25
BR112017003898B1 (pt) 2022-10-18
DK3186244T3 (da) 2020-07-13
CN110790789B (zh) 2023-05-12
CN107074826B (zh) 2020-05-22
AU2015308988B2 (en) 2018-04-26
KR102398714B1 (ko) 2022-05-17
PL3186244T3 (pl) 2020-11-16
PL3572410T3 (pl) 2022-10-03
KR20200035482A (ko) 2020-04-03
EA201890648A3 (ru) 2019-02-28
AU2015308988C1 (en) 2018-09-06
EP3572410B1 (en) 2022-07-20
CA3128645C (en) 2023-06-27
BR112017003898A2 (pt) 2017-12-05
EP3572410A1 (en) 2019-11-27
JP2017526677A (ja) 2017-09-14
JP6663424B2 (ja) 2020-03-11
PH12019501919A1 (en) 2020-09-14
EA031106B1 (ru) 2018-11-30
SG11201701172SA (en) 2017-03-30
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
US20190100541A1 (en) 2019-04-04
PH12017500184B1 (en) 2017-06-28
US20170267705A1 (en) 2017-09-21
PH12017500184A1 (en) 2017-06-28
HUE050705T2 (hu) 2020-12-28
CA2956251A1 (en) 2016-03-03
US10654877B2 (en) 2020-05-19
CN107074826A (zh) 2017-08-18
CA3128645A1 (en) 2016-03-03
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
AU2015308988A1 (en) 2017-02-23
MX2017002328A (es) 2017-05-22

Similar Documents

Publication Publication Date Title
CY1122945T1 (el) Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου
CY1123598T1 (el) Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1121901T1 (el) Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1123592T1 (el) Αναστολεας κινασης aurora a
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
CY1122364T1 (el) Αναστολεις της ezh2
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
CY1118756T1 (el) Νεα παραγωγα πυρρολιου, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
CY1123703T1 (el) Υψηλης πυκνοτητας διαυγη υγρα αλμης
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
MX365590B (es) Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.
EA201790327A1 (ru) Соединения замещенного пиперидина
CY1121722T1 (el) Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης